Evgen Pharma plc (LON:EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will hold its Annual General Meeting this afternoon in Manchester. At the AGM, the Company’s Chairman, Barry Clare, will make the following statement:
“The current year is progressing well for our Company. SFX-01, our lead product candidate, continues to be tested in two Phase II trials in different indications, breast cancer and subarachnoid haemorrhage.
“Interest in SFX-01 and sulforaphane-based science continues apace in the academic and translational medicine communities. Earlier this month, we announced that the Manchester Cancer Research Centre will conduct preclinical research of SFX-01 in triple negative breast cancer. Today, we can announce that the Company and the Skeletal Biology Group at the Royal Veterinary College, University of London, has secured grant funding to continue its collaboration and build on earlier encouraging preclinical results demonstrating the potential of SFX-01 as a treatment for osteoarthritis. The RVC will be releasing a separate announcement later today.
“These investigator-led studies underline the broad therapeutic potential of SFX-01 and extend the Company’s commercial presence in sulforaphane-based research. Our primary focus remains on our two Phase II trials and we look forward to making further progress with these trials in the year ahead.”
Dr Stephen Franklin, Evgen Pharma’s CEO, will give a corporate presentation at the AGM. A copy of the presentation is available at the Company’s website, www.evgen.com.